NextCure (NXTC) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for June 20, 2025, to be held virtually, allowing electronic voting and Q&A participation.

• Key business includes director elections, auditor ratification, executive compensation votes, a reverse stock split proposal, and potential adjournments to solicit proxies.

• Focus remains on developing innovative cancer therapies, with recent milestones in antibody-drug conjugate (ADC) programs and preclinical assets.

Voting matters and shareholder proposals

• Election of three Class III directors for three-year terms.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year 2025.

• Advisory vote on executive compensation (Say-on-Pay) and on the frequency of such votes (Say-on-Frequency), with the Board recommending annual votes.

• Approval sought for a reverse stock split at a ratio between 1:5 and 1:15, at the Board's discretion, to maintain Nasdaq listing compliance.

• Proposal to allow adjournment of the meeting to solicit additional proxies if needed.

Board of directors and corporate governance

• Board consists of seven members, majority independent, with diverse expertise in biotech, finance, and clinical development.

• Board committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members.

• Chair and CEO roles are separated to reinforce board independence.

• Annual review of CEO succession planning and director education.

• Code of business conduct and ethics, insider trading, and clawback policies in place.